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In melanomas, as in most solid cancers, surgery is the basic 
method that leads to a permanent cure. The last 2 years have 
brought a debate and changes in the recommendations for 
therapeutic management after positive (confirming a meta-
stasis) biopsy of the sentinel node in relation to completion 
lymph node dissection (CLND).  
Results of a prospective multi-center Multicenter Selective 
Lymphadenectomy Trial 1 (MSLT-1) study indicate that the 
biopsy of a sentinel node in patients with melanoma:
• allows for identifying groups at high risk of cancer spread, 
• helps to properly determine the severity of the disease, 
• provides excellent regional control,
• enables patients to be qualified for clinical trials according 
to the same criteria. 
The MSLT-1 study showed no improvement in survival 
time to relapse and in total survival time in the whole analyzed 
group of patients undergoing sentinel node biopsy compared 
to the observed group [1].
Results of two published studies: DeCOG-SLT and MSLT-II 
with random selection of patients [2, 3], one of which, howe-
ver, did not have sufficient statistical power [3], did not show 
improvement in total melanoma-specific survival time [2] and 
disease-free survival time from distant metastases in patients 
undergoing the CLND [3]. However, the survival time of di-
sease-free patients undergoing the CLND was longer (fewer 
relapses in the nodal area). A summary of the trial results is 
presented in Table I. At the same time, the basic prognostic 
role of sentinel node biopsy was confirmed. 
According to Polish and American recommendations 
(NCCN, ASCO/SSO) [4–6], radical lymphadenectomy should 
be considered after histopathological examination of mela-
noma metastases in the node or sentinel nodes (especially 
at micro-metastases > 1 mm or when the risk of metastases 
to other nodes is higher). This is important because in other 
lymph nodes (non-sentinel lymph node – NSLN) melanoma 
metastases are found by routine histopathological methods in 
about 20–30% of patients [7]. Close observation and ultraso-
und examination of the lymphatic flow area every 4–6 months 
may also be acceptable. 
Thus, the CLND remains one of the standard methods of 
management after a positive biopsy of the sentinel node. So 
what are the arguments in favor of this course of management? 
First of all, in both clinical trials a group of patients with 
very small metastases to the sentinel node (mainly up to 1 mm) 
was over-represented. It can therefore be considered that, 
under real conditions, patients with larger metastases in the 
sentinel node may benefit from the CLND. Secondly, the lack 
of CLND implementation does not allow some patients to 
properly qualify for staging, because there is no information 
about possible metastases in NSLN. And such information has 
a prognostic value and may affect the qualification for com-
plementary treatment. On the other hand, CLND significantly 
reduces the risk of melanoma recurrence in regional lymphatic 
flow (based on Multicenter Selective Lymphadenectomy Trial-II 
(MSLT-II): this local lymphatic basin control was 92±1.0% after 
CLND vs. 77±1.5% without CLND, p < 0.001) [2] – which may be 
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significant for some patients. Moreover, all the studies – with 
a systemic complementary treatment currently registered 
for routine use (anti-PD-1 nivolumab/pmebrolizumab immu-
notherapy or molecularly directed therapy with BRAF/MEK 
dabrafenib inhibitors with trametinib) [8–11] – were based 
on the group of patients after CLND and showed an impro-
vement in results after adjuvant treatment. Finally, any patient 
on whom the CLND is not performed must be subject to strict 
observation, which includes ultrasound of regional lymphatic 
flow every 3–4 months, and under clinical conditions this is 
not always easy for the patient.
To sum up the discussion whether a complementary 
lymphadenectomy should be performed in melanoma after 
a positive biopsy of the sentinel node – the answer is yes, but 
not in every patient. It should be noted that the role of the 
CLND in the near future will be individualized and decreasing.
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Table I. Results of trials comparing the CLND with observation after positive biopsy of the sentinel node





483 34 months Observation vs. CLND: OS HR 1.02 p = 0.95, 10 years’ 62.6% vs. 61.9%; 
RFS HR 0.959 DMFS 1.19 10 years’ 55.8% vs. 55.5%
MSLT-II
Faries et al.
1755 43 months Observation vs. CLND: MSS HR 1.08 p = 0,42; DMFS HR 1.1; DFS CLND 
68% vs. observation 63%
